2022
DOI: 10.1016/j.chembiol.2022.01.001
|View full text |Cite
|
Sign up to set email alerts
|

Small-molecule inhibitors of ferrochelatase are antiangiogenic agents

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
4
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(4 citation statements)
references
References 57 publications
0
4
0
Order By: Relevance
“…Ferrochelatase (FECH), the key enzyme for the final step of heme biosynthesis in eukaryotes, functions to insert a Fe 2+ ion into the center of the porphyrin ring of protoporphyrin IX (PPIX) [ 22 ]. In our previous study, we demonstrated that DMC binds to FECH to inhibit its enzymatic activity [ 12 ].…”
Section: Resultsmentioning
confidence: 99%
“…Ferrochelatase (FECH), the key enzyme for the final step of heme biosynthesis in eukaryotes, functions to insert a Fe 2+ ion into the center of the porphyrin ring of protoporphyrin IX (PPIX) [ 22 ]. In our previous study, we demonstrated that DMC binds to FECH to inhibit its enzymatic activity [ 12 ].…”
Section: Resultsmentioning
confidence: 99%
“…This strategy is based on the inhibition of enzyme activity, leading to the accumulation of PpIX in cells. Several inhibitors of ferrochelatase activity have been identified [90,91]. Sishtla et al [92] described that nearly 20,000 compounds from ChemDiv and ChemBridge libraries were evaluated on a high-throughput screen to assess their effect at 10 µM on ferrochelatase activity.…”
Section: -Ala In Antimicrobial Photodynamic Inactivationmentioning
confidence: 99%
“…Furthermore, FECH inhibition decreased HRECs oxidative phosphorylation and mitochondrial complex IV, reduced mitochondrial fusion and mass, indicating for the first time that FECH-mediated mitochondrial heme metabolism and dysfunction regulated ECs angiogenesis [ 249 ]. Through high-throughput screening, a class of triazolopyrimidinone was identified to competitively inhibit FECH and angiogenesis in vitro and in vivo, indicating FECH inhibitors could be effective in treating retinal neovascularization and other diseases [ 250 ].…”
Section: Other Mitochondrial Protein In Ecs Angiogenesismentioning
confidence: 99%